A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer

Condition:   HER2-Positive Early Breast Cancer Interventions:   Drug: Pertuzumab and Trastuzumab FDC SC;   Drug: Pertuzumab IV;   Drug: Trastuzumab IV Sponsor:   Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials